Category Archives: Business and Investments

Latest From Business and Investments

BIO CEO Company Snapshot: ImmunoGen, Inc.

immunogen-thumb

In the latest Company Snapshot for the 2012 BIO CEO & Investor Conference in New York City, we’re profiling ImmunoGen, Inc. which will be presenting at the event. We spoke with ImmunoGen, Inc. CEO Daniel Junius and he outlined his organization’s priorities and challenges as well as how his company differentiates themselves from the competition. Company Snapshot What are the short-term and long-term priorities for your company? Our highest priority today is building and advancing our pipeline Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Managing in a Cost-Constrained Environment

medicine

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , , ,

Virginia is for (Science) Lovers

Pam Moran

In Albemarle County, Virginia, the public school division is debuting a Health and Medical Sciences Academy this fall. Public high school students throughout the county will apply for a four-year program with a curricular concentration on skill sets that will serve state and national needs in the healthcare, pharmaceutical and research industries. In the following guest blog post, Dr. Pamela R. Moran, Superintendent of Albemarle County Public Schools, discusses this innovative program and offers insight Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,

Reviewing the drug class of 2011

The drug class of 2011 was larger than the past few graduating classes. We count over 30 new “innovative” drugs found among the list of FDA approvals last year. This is in contrast to the 20-something range of the past few years. On the list are some clear breakthrough treatments and a few glimpses of “the future of biotech”. The specific drugs are listed further below, but first a big picture view: Ten of the approvals were for biologics, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Venture Capital increases in 2011, but…

The National Venture Capital Association (NVCA) has released their 4Q 2011 numbers for biotech venture financing in the US. The report echoes the global numbers already out from BioCentury and BioWorld – a boost in investment for 2011. The take away, however, is not the total amount, but 1) the drop in the total number of biotech deals, and 2) the drop in start-up, early-stage deals from 2010. The total number of deals near 447 was down Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , ,